A307750 Stock Overview
Operates as a chemical total solutions provider in South Korea.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
KUKJEON PHARMACEUTICAL Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩5,400.00 |
| 52 Week High | ₩8,080.00 |
| 52 Week Low | ₩4,990.00 |
| Beta | -1.11 |
| 11 Month Change | 6.09% |
| 3 Month Change | -1.64% |
| 1 Year Change | -18.55% |
| 33 Year Change | -42.61% |
| 5 Year Change | n/a |
| Change since IPO | -28.10% |
Recent News & Updates
Shareholder Returns
| A307750 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 1.7% | -1.5% | -4.0% |
| 1Y | -18.6% | 14.8% | 2.2% |
Return vs Industry: A307750 underperformed the KR Pharmaceuticals industry which returned 14.8% over the past year.
Return vs Market: A307750 underperformed the KR Market which returned 2.2% over the past year.
Price Volatility
| A307750 volatility | |
|---|---|
| A307750 Average Weekly Movement | 3.1% |
| Pharmaceuticals Industry Average Movement | 4.1% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in KR Market | 11.1% |
| 10% least volatile stocks in KR Market | 2.2% |
Stable Share Price: A307750 has not had significant price volatility in the past 3 months.
Volatility Over Time: A307750's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1972 | 167 | Jongho Hong | www.kukjeon.co.kr |
KUKJEON PHARMACEUTICAL Co., Ltd operates as a chemical total solutions provider in South Korea. It provides various chemical-based products and services; and after-sales services, such as research and development, production, quality control, and DMF services. The company manufactures active pharmaceutical ingredients; and offers molecular design and technical support.
KUKJEON PHARMACEUTICAL Co., Ltd Fundamentals Summary
| A307750 fundamental statistics | |
|---|---|
| Market cap | ₩264.97b |
| Earnings (TTM) | ₩1.35b |
| Revenue (TTM) | ₩129.43b |
196.1x
P/E Ratio2.0x
P/S RatioIs A307750 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A307750 income statement (TTM) | |
|---|---|
| Revenue | ₩129.43b |
| Cost of Revenue | ₩104.53b |
| Gross Profit | ₩24.90b |
| Other Expenses | ₩23.55b |
| Earnings | ₩1.35b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 27.54 |
| Gross Margin | 19.24% |
| Net Profit Margin | 1.04% |
| Debt/Equity Ratio | 79.1% |
How did A307750 perform over the long term?
See historical performance and comparison